The First Application to Grow Medical Cannabis Was Received in Poland

To date, only one application for a permit to cultivate cannabis for medical purposes has been submitted. This information was provided by the Ministry of Health, responding to a parliamentary interpellation.

However, the process is on hold and the application remains unprocessed. Current regulations allow the cultivation of medical cannabis, but only under strict, controlled conditions, conducted by research institutions.

Read more about medical cannabis cultivation in Poland and find the latest cannabis news of the day with the Hemp.im mobile app.

New regulations opening the way for the cultivation of cannabis for medical purposes

The ordinance dated March 22nd, 2022 amended the Anti-Drug Addiction Law, allowing the cultivation of hemp other than fibrous plants. According to Hanna Gill-Piątek, the author of the interpellation, this amendment to the law has a major impact on the entire medical cannabis sector, opening the way for the establishment of Polish medical cannabis plantations, which in turn will contribute to lowering its prices in pharmacies.

Cultivation of cannabis for medical purposes is possible only under certain controlled conditions – in research institutes under the supervision of the Ministry of Agriculture and Rural Development. These institutions must have the appropriate infrastructure. It is also necessary to obtain a permit for the cultivation and harvesting of cannabis from the Chief Pharmaceutical Inspector, who must consult his decision with the provincial police chief after the crop has been properly secured.

The MP noted that the regulation of the Minister of Internal Affairs and Administration on securing the cultivation of hemp other than fibrous hemp, as well as storing the harvest of herb or resin from such hemp, was not issued until January 4th, 2023.

Highlighting the prospects, the MP noted that “products based on the Polish pharmaceutical raw material are likely to appear in pharmacies only in 2024.”

Inquiries to the health ministry on medical cannabis cultivation

Hanna Gill-Piątek decided to ask questions to the Health Ministry about the number of applications for permission to cultivate hemp other than fibrous plants submitted by authorized entities. She wanted to know how many of them had been processed, how many had received a positive response and how many had received a negative response. She also asked about the total area of cannabis cultivation allowed by the permits issued and the average waiting time for processing the application.

Only one application for medical cannabis in Poland

Deputy Health Minister Maciej Miłkowski noted that only one application for a permit to cultivate cannabis for pharmaceutical production has been received so far. “This application has not yet been processed due to the suspension of proceedings at the request of a party,” the deputy minister added.

He also noted that applications submitted correctly and without deficiencies are processed within 30 days, taking into account the suspension of the deadline for the time necessary for the relevant police department to issue an opinion.

__

(Featured image by Terrance Barksdale via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.